Trial Profile
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of a Single Dose of PRT-201 Administered Immediately After Arteriovenous Graft Creation in Patients With Chronic Kidney Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Oct 2016
Price :
$35
*
At a glance
- Drugs Vonapanitase (Primary)
- Indications Renal failure
- Focus Adverse reactions
- Sponsors Proteon Therapeutics
- 19 Dec 2014 New trial record